Background: Ultrasound molecular imaging was used to evaluate the therapeutic effects of antioxidant therapy with EUK-207, which has superoxide dismutase and catalase activities, on suppressing high-risk atherosclerotic features.
Noninvasive imaging is increasingly used in the process of drug development to assess the efficacy and safety of drugs in animal models and clinical trials. Molecular imaging in particular has been valuable in preclinical research for confirming on-target efficacy of candidate drugs and for dose optimization and in clinical trials for selecting patients who are most likely to benefit from therapy. 1 In atherosclerotic disease, ultrasound molecular imaging has been used for the assessment of endothelial inflammatory activation, including expression of adhesion molecules, which happens early in atherogenesis. 2, 3 One of the major contributors to endothelial activation in atherosclerosis is oxidative stress, which occurs directly through reactive oxygen species (ROS) [4] [5] [6] [7] [8] and through oxidatively-modified low-density lipoprotein. 8, 9 ROS also have been shown to suppress cleavage of von Willebrand factor (VWF) multimers on the endothelial surface, 10 which can lead to arterial platelet adhesion and promotion of plaque progression. 11 Plaque formation in atherosclerotic mouse models is inhibited by gene alterations that reduce ROS generation and is increased by deletion of antioxidant enzymes, including certain superoxide dismutase (SOD) isoforms. 6, 7, 12 Among humans, carotid intimal thickening is lower in those with genetic alterations that reduce ROS production. 13 These observations have established vascular ROS as a therapeutic target in atherosclerosis, although antioxidant drugs that are safe and effective in humans have not been identified. When evaluating new antioxidants, molecular imaging of the endothelial responses is likely to provide important data on in vivo efficacy. In this study we used contrast-enhanced ultrasound (CEU) molecular imaging to test whether potent multifunctional antioxidant therapy could suppress high-risk plaque features, particularly when started early in atherosclerosis. The salenMn compound EUK-207 was studied in a murine model on the basis of its multifunctional antioxidant actions as a combined SOD and catalase mimetic.
14 In vivo molecular imaging of endothelial phenotype was used to assess whether EUK-207 reduces endothelial adhesion molecule expression, endothelial-associated VWF in its active form (exposure of its A1 binding domain for platelet glycoprotein Iba [GPIba]), and platelet-endothelial adhesion.
METHODS

Animals and Study Design
The study was approved by Animal Care and Use Committee at Oregon Health & Science University. Mice with susceptibility to age-related atherosclerosis through gene-targeted deletion or ''double knockout'' (DKO) of the low-density lipoprotein receptor and apolipoprotein-B messenger ribonucleic acid editing enzyme catalytic polypeptide 1 (Apobec-1) on a C57Bl/6 background were studied. 15 Mice were fed a chow diet ad libitum. Evaluation of plaque by molecular imaging and histology was performed at either 20 weeks of age (equivalent to the end of the first quarter of the average life span or 20 human years), when DKO mice have early intramural atherosclerosis (fatty streaks) of the proximal aorta, or at 40 weeks of age (just over half of the average life span or close to 45 human years), at which time there are moderate to severe macrophagerich intraluminal plaques. 2 To evaluate the effects of short-term therapy at early or late stages of disease, mice were treated with EUK-207 or vehicle for 8 weeks starting at either 12 weeks (EUK-207, n = 12; control, n = 11) or 32 weeks (EUK-207, n = 9; control, n = 10) of age for later study at 20 and 40 weeks. To evaluate long-term therapy, EUK-207 was given for 28 weeks starting at 12 weeks (n = 8) and studied at 40 weeks. Noninvasive imaging studies were performed before therapy (baseline) and after therapy. On each study day, mice were anesthetized with inhaled isoflurane (1.0%-1.5 %), and a jugular vein was cannulated for intravenous administration of contrast material.
EUK-207 Treatment
EUK-207 (9 mg/mL in 5% mannitol; provided by Bernard MalfroyCamine, MindSet Rx, Arlington, MA) was loaded into an osmotic minipump (model 1004; ALZET Osmotic Pumps, Cupertino, CA) programmed for an infusion rate of 0.11 mL/h over 28 days for a calculated dose rate of approximately 1 mg/kg/day. Sham therapy was performed with 5% mannitol alone. Mice were anesthetized with inhaled isoflurane, and pumps were placed in the ventral hindlimb subcutaneous tissue through a small incision that was subsequently closed. Pumps were exchanged every 4 weeks using the same site unless significant scar tissue was encountered. There were no pump failures.
Targeted Microbubble Preparation
Full methods for preparation of microbubbles targeted to platelet GPIba, ''activated'' VWF, or P-selectin are provided in the Appendix (available at www.onlinejase.com). Briefly, biotinylated lipid-shelled decafluorobutane microbubbles were prepared, and surface conjugation of targeting ligands was performed using recombinant VWF A1-domain for microbubbles targeted to platelet GPIba, 16 a GPIba peptide for microbubbles targeted to activated VWF, 3 and a monoclonal antibody (RB40.34; BD Biosciences, San Jose, CA) for microbubbles targeted to P-selectin. Control nontargeted microbubbles were prepared using a nonspecific, nonbinding control monoclonal antibody (R3-34; BD Biosciences).
In Vivo Molecular Imaging CEU molecular imaging of the ascending aorta and proximal aortic arch in long axis was performed using a linear-array probe (15L8; Sequoia, Siemens Medical Systems, Mountain View, CA) using multipulse phase inversion and amplitude modulation imaging at 7 MHz, a dynamic range of 55 dB, and a mechanical index of 0.97. Images were acquired 8 min after intravenous injection of targeted or control microbubbles (1 Â 10 6 ) to allow decay of almost all of the signal from freely circulating microbubbles in the blood pool. 17 Signal from retained microbubbles alone was determined as previously described by acquiring the first ultrasound frame and then digitally subtracting several averaged frames obtained after complete destruction of microbubbles in the imaging field to eliminate signal from the low concentration of freely circulating microbubbles in the blood pool. 18 Intensity was measured from a region of interest that was standardized by encompassing the entire ascending aorta from just beyond the sinuses to just beyond the origin of the brachiocephalic artery. Region selection was guided by high-frequency fundamental two-dimensional imaging at 14 MHz performed by switching from 7 MHz contrast-specific imaging at the end of each video capture. Because low-grade arterial attachment of nontargeted microbubbles occurs from vascular inflammation in an age-dependent fashion in DKO mice, 3 all data were expressed as a difference in signal from control agent (control nontargeted microbubbles).
Assessment of Left Ventricular Function and Aortic Compliance
Echocardiography (Vevo 2100; Visualsonics, Toronto, Ontario, Canada) was performed using a high-frequency (30-MHz) phasedarray probe. Short-axis images at the left ventricular (LV) midpapillary muscle level were acquired, and LV systolic function was quantified by (1) This method relies on the increase in flow velocity (reduction in transit time) in rigid noncompliant arteries due to lack of distension and less conversion from kinetic to potential energy. Pulse-wave transit time was measured by the time delay of the onset of systolic pressure rise on pulse-wave Doppler in the proximal ascending aorta and the femoral artery approximately 0.5 mm from the pudendoepigastric trunk. Measurements were averaged for three cardiac cycles and were not normalized to blood pressure.
Histology
Full methods are provided in the Appendix (available at www. onlinejase.com). Briefly, perfusion-fixed short axes from the proximal ascending aorta to the distal aortic arch were obtained from EUK-207-or sham-treated mice at 20 or 40 weeks of age. Plaque area was determined using Masson's trichrome. Fluorescent immunohistochemistry for Mac-2 was used for macrophage staining.
Statistical Analysis
Data were analyzed using Prism version 5.0 (GraphPad Software, La Jolla, CA). Comparisons between pre-and posttherapy values were made using paired Student's t test. Groupwise differences were assessed using the Mann-Whitney U test for data that were determined to be non-normally distributed by D'Agostino and Pearson omnibus test. For data with normal distribution, groupwise differences were assessed using one-way analysis of variance with post hoc Student's t test and Bonferroni correction when appropriate for multiple comparisons. Differences were considered significant at P < .05.
RESULTS
Cardiovascular and Vascular Functional Imaging
Because oxidative stress associated with hyperlipidemia and inflammation can contribute to LV remodeling and changes in myocardial contractile function, 20 echocardiographic evaluation of LV function was performed in control and EUK-207 mice at 20 or 40 weeks of age. There were no major treatment-related differences in either midventricular fractional shortening on twodimensional imaging or global circumferential strain on speckletracking echocardiography (Figure 1 ). Treatment with EUK-207 produced a modest improvement of pulse-wave transit time in the DKO mice at 40 weeks of age that were treated with longduration therapy of 28 weeks but not with short-duration therapy of 8 weeks (Figure 2 ).
Molecular Imaging of Vascular Phenotype
On molecular imaging of the proximal ascending aorta in DKO mice at 20 weeks of age, short-term (8-week) therapy with EUK-207 compared with sham-treated controls produced only nonsignificant trends for lower signal enhancement for microbubbles targeted against endothelial P-selectin, VWF A1-binding domain reflecting endothelial-associated activated VWF, and GPIba reflecting platelet adhesion to the vascular wall (Figure 3 
Plaque Histology
Consistent with previous studies with DKO mice, in shamtreated mice there was an age-dependent increase in aortic plaque area between 20 and 40 weeks of age (10,386 6 4,614 vs 133,063 6 28,522 mm 2 , P < .0001). When given for short duration (8 weeks), EUK-207 had minimal effect on plaque size for 20-and 40-week-old DKO mice (Figures 4 and 5) . However, therapy for 28 weeks resulted in the near complete absence of plaque development in both the aortic root and distal ascending aorta. Interobserver variability in measurement of plaque area was excellent (intraclass correlation coefficient = 0.98; 95% CI: 0.94-0.99; r 2 = 0.97). There was a significant agedependent increase in plaque macrophage content (Mac-2) in sham-treated control mice and nearly complete absence of intramural macrophages in 40-week mice treated with EUK-207 for 28 weeks.
DISCUSSION
Atherosclerosis is recognized to be an indolent disease process that, in humans, develops over decades in response to chronic vascular inflammatory, mitogenic, and prothrombotic processes. Short-term therapy with anti-inflammatory or antithrombotic therapies can prevent recurrent acute atherothrombotic events in late-stage disease. However, it is widely believed that chronic long-term suppression of disease-related pathways is needed to permanently arrest or even prevent the development of atherosclerotic plaques. However, convincing data on the short-and long-term effects of antioxidant therapy have been limited by the paucity of in vivo methods for directly examining biologic changes that occur in the vessel wall in response to novel antioxidant therapies that can then be correlated with histology. In this study, CEU molecular imaging was applied to evaluate the beneficial effects of a multifunctional antioxidant, EUK-207, on the vascular endothelium.
Our results indicate that the short-term beneficial effects of EUK-207 to reduce endothelial activation and platelet-endothelial interactions leads to a profound reduction in plaque size and inflammation when therapy is continued for a long duration. Initiation of therapy late in the disease process had a profound effect to reduce endothelial activation and platelet adhesion; however, there were no effects on plaque size or macrophage content, either because 10 weeks was not enough time to show morphologic change or because a reduction of endothelial activation is not sufficient by itself to promote advanced plaque regression.
HIGHLIGHTS
Multifunctional anti-oxidants can prevent atherosclerosis when started early. Molecular imaging is a sensitive way to evaluate atheroprotective therapies. Endothelial activation and platelets are markers of aggressive atherosclerosis.
The selection of EUK-207 as a therapeutic compound in this study was based on the notion that potent antioxidant therapy could reduce not only plaque inflammation but also platelet-endothelial interactions that have been implicated in promoting plaque progression and monocyte recruitment even in early disease. 11, 21 Oxidative stress in atherosclerosis is generated from a variety of sources. Resident vascular cells produce free radicals through the enzymatic activity of NADPH oxidase complexes, endothelial xanthineoxidase, uncoupled endothelial nitric oxide synthase, and mitochondrial respiration. 6, 8, 22 Inflammatory cells and platelets also contribute to vascular oxidative stress. 23 The suppression or quenching of antioxidant enzyme families such as SOD and catalase can also contribute to plaque oxidative burden. 6 There are many pathways by which oxidative stress leads to plaque progression and unstable plaque phenotype. In this study we used molecular imaging to specifically evaluate vascular endothelial events triggered by oxidative stress. Vascular inflammation occurs through signaling of specific receptors such (lectin-like oxidized low-density lipoprotein receptor, Toll-like receptors, and scavenger receptors) 6, 9 or inhibition of anti-inflammatory processes. 22 As a result, there is upregulation of adhesion molecules including P-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 that are involved in leukocyte recruitment and the endothelial production of pro-inflammatory chemokines. 4, 5 Platelet recruitment is yet another proatherosclerotic consequence of oxidative stress that occurs, in part, from endothelial events. Increased ROS can result in loss of the normal antiplatelet activities of both nitric oxide and prostacyclin. 22 Reviewed elsewhere, adverse oxidative events in atherosclerosis can lead to platelet recruitment through interaction of endothelial VWF with the GPIba component of the platelet glycoprotein Ib/glycoprotein V/glycoprotein IX complex. 11 This may occur in part from oxidative inhibition of proteases that cleave endothelial-associated VWF. 10, 24 The platelet-endothelial interactions that ensue can amplify inflammation through a variety of signaling pathways or through direct platelet-mediated recruitment of monocytes.
11
On the basis of the extensive proatherogenic endothelial effects of ROS discussed above, we used CEU molecular imaging to assess the beneficial effects of EUK-207 on selectin expression, endothelialassociated VWF, and endothelial recruitment of platelets. CEU is uniquely suited for this application for several reasons. First, it uses targeted microbubbles that are confined to the intravascular compartment, thereby giving us confidence that signal was from events occurring at the interface of the endothelium and blood pool. For microbubbles targeted to platelets and VWF, we used recombinant biologic versions of the endogenous binding receptors that are able to ligate particles at physiologic shear. Finally, microbubbles that do not attach are rapidly cleared from the blood pool, thereby providing the opportunity to image multiple endothelial targets in a relatively rapid fashion. The targeted microbubble agents used in this study have been validated previously. 2, 3, 16 We were also leveraging information from prior validation studies that demonstrated that the markers of endothelial activation in this study are expressed at high levels at all stages of atherosclerosis, even early, consistent with the notion that macrophage accumulation occurs very gradually in response to a consistent high level of endothelial activation. 2, 3, 16 In this study, imaging of these same molecular processes was used in DKO mice as a readout for the endothelial effects of EUK-207, which has been shown previously to mitigate other oxidatively mediated diseases such as injury radiation injury and ischemia-reperfusion injury. [25] [26] [27] Our data indicate the presence of beneficial short-and long-term effects of EUK-207 on endothelial phenotype, particularly in late-stage disease, when endothelial abnormalities tend to be more severe. It should be noted that ''negative'' intensity values for normalized signal intensity (control À targeted signal) are likely because in the absence of any targeted attachment, the presence of targeting ligands can stoichiometrically prevent nonspecific retention of microbubbles. 28 Plaque histology yielded important information on the effect of EUK-207 on plaque development and content. When paired with molecular imaging data, histology also provided insight into the temporal relationship between the modification of endothelial phenotype and plaque progression. Our findings indicate that potent antioxidant therapy can dramatically reduce endothelial activation, yet the effects on plaque size and content with shortterm therapy are modest. On the other hand, long-term therapy when started early can have profound effects on preventing plaque development.
With regard to clinical implications, our findings suggest that (1) potent anti-inflammatory therapies will be most effective when given at early stages of disease to very high-risk individuals, and (2) trials evaluating the effect of new antioxidant therapies in patients are likely to require extended periods of follow-up. This latter issue provides a strong basis for molecular imaging of endothelial cell phenotype or other forms of vascular inflammation imaging. These techniques may be helpful in clinical trials by demonstrating beneficial early vascular responses to antioxidant therapies with compounds such as EUK-207 to ensure ''on-target'' cellular and molecular effects before any expected effects on plaque size or composition. There is precedent in this strategy, such as the recent demonstration of lack of effect of dalcetrapib on positron emission tomographic imaging of inflammation in patients with atherosclerotic disease, which has been useful for understanding lack of therapeutic benefit in clinical trials. There are limitations of the study that must be acknowledged. Experience with vitamin-based antioxidants has taught us that the effects of oxidative stress in atherosclerosis and the benefits of antioxidants found in murine models do not guarantee replication in humans. 30 However, the mechanism of action of EUK-207 is profoundly different from that of vitamin-based antioxidants, as EUK-207 targets both ROS and reactive nitrogen species and acts catalytically, which conveys distinct advantages over compounds that are more specific and act in a stochiometric way. We also cannot state with certainty how many of the beneficial effects of EUK-207 on plaque size and content were attributable to its effects on the endothelium. We did not directly compare molecular imaging signal with immunohistochemistry for P-selectin and VWF, because these molecules are normally stored in endothelial Weibel-Palade bodies, which are present on histology. Platelet signal has already been validated against histology. 3 It is important to realize that a murine models do not necessarily fully capitulate human disease in terms of location of disease, shear forces, the temporal course of disease development, and the contrived genetic nature of disease susceptibility, which starts from birth. Finally, we have not necessarily proved that any of the processes that were imaged on molecular imaging are responsible for EUK-207's beneficial effects on plaque growth. This will be proved only by showing lack of additional effect in animals with genetic deletion of P-selectin or animals treated with GPIba antagonists.
CONCLUSION
The results of this study indicate that the SOD and catalase mimetic EUK-207 acts to reduce endothelial P-selectin expression and to suppress platelet-endothelial interactions by inhibiting endothelial-associated VWF. The beneficial anti-inflammatory and antiplatelet endothelial effects of EUK-207 occurred with even short duration of therapy, yet meaningful effects on reducing plaque size and content were found only with long-term therapy, indicating a slow cumulative effect of antioxidant therapy. These findings are also important for understanding how the beneficial effects of potent antioxidant on plaque morphometry may only be Figure 3 Thoracic aorta CEU molecular imaging data (mean 6 SEM) for DKO mice at (A) 20 weeks of age, (B) 40 weeks of age after 8 weeks of therapy, and (C) 40 weeks of age after 28 weeks of therapy. Data are normalized by subtracting background signal intensity from control microbubbles (MBs), which, for some conditions, stochastically resulted in ''negative'' values when there was no selective enhancement. *P < .01 for the targeted agent versus control MBs. (D) Images illustrate two-dimensional ultrasound of the thoracic aorta (left) and background-subtracted color-coded (color scale at bottom) CEU images of platelet adhesion (MB P ; right) for 40-week-old DKO control-treated mice or mice treated with EUK-207 for 8 or 28 weeks. manifest with long-term therapy, whereas effects discoverable on molecular imaging of endothelial phenotype may be seen much earlier.
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